2016 US lymphoid malignancy statistics by World Health Organization subtypes

Lauren R. Teras, Carol E. Desantis, James R Cerhan, Lindsay M. Morton, Ahmedin Jemal, Christopher R. Flowers

Research output: Contribution to journalArticle

223 Citations (Scopus)

Abstract

Collectively, lymphoid neoplasms are the fourth most common cancer and the sixth leading cause of cancer death in the United States. The authors provide contemporary lymphoid neoplasm statistics by subtype based on the 2008 World Health Organization classifications, including the most current US incidence and survival data. Presented for the first time are estimates of the total numbers of US lymphoid neoplasm cases by subtype as well as a detailed evaluation of incidence and survival statistics. In 2016, 136,960 new lymphoid neoplasms are expected. Overall lymphoma incidence rates have declined in recent years, but trends vary by subtype. Precursor lymphoid neoplasm incidence rates increased from 2001 to 2012, particularly for B-cell neoplasms. Among the mature lymphoid neoplasms, the fastest increase was for plasma cell neoplasms. Rates also increased for mantle cell lymphoma (males), marginal zone lymphoma, hairy cell leukemia, and mycosis fungoides. Like incidence, survival for both mature T-cell lymphomas and mature B-cell lymphomas varied by subtype and by race. Patients with peripheral T-cell lymphomas had among the worst 5-year relative survival (36%-56%, depending on race/sex), while those with mycosis fungoides had among the best survival (79%-92%). For B-cell lymphomas, 5-year survival ranged from 83% to 91% for patients with marginal zone lymphoma and from 78% to 92% for those with hairy cell leukemia; but the rates were as low as 47% to 63% for patients with Burkitt lymphoma and 44% to 48% for those with plasma cell neoplasms. In general, black men had the lowest survival across lymphoid malignancy subtypes. These contemporary incidence and survival statistics are useful for developing management strategies for these cancers and can offer clues regarding their etiology.

Original languageEnglish (US)
JournalCA Cancer Journal for Clinicians
DOIs
StateAccepted/In press - 2016

Fingerprint

Survival
Neoplasms
Incidence
Plasma Cell Neoplasms
Hairy Cell Leukemia
Lymphoma
Mycosis Fungoides
B-Cell Lymphoma
Peripheral T-Cell Lymphoma
Mantle-Cell Lymphoma
Burkitt Lymphoma
T-Cell Lymphoma
Cause of Death
B-Lymphocytes

Keywords

  • Chronic lymphocytic leukemia
  • Epidemiology
  • Hodgkin disease
  • Multiple myeloma
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology
  • Oncology

Cite this

2016 US lymphoid malignancy statistics by World Health Organization subtypes. / Teras, Lauren R.; Desantis, Carol E.; Cerhan, James R; Morton, Lindsay M.; Jemal, Ahmedin; Flowers, Christopher R.

In: CA Cancer Journal for Clinicians, 2016.

Research output: Contribution to journalArticle

Teras, Lauren R. ; Desantis, Carol E. ; Cerhan, James R ; Morton, Lindsay M. ; Jemal, Ahmedin ; Flowers, Christopher R. / 2016 US lymphoid malignancy statistics by World Health Organization subtypes. In: CA Cancer Journal for Clinicians. 2016.
@article{2c201dcb7e464e76a843e50ddd15dcfc,
title = "2016 US lymphoid malignancy statistics by World Health Organization subtypes",
abstract = "Collectively, lymphoid neoplasms are the fourth most common cancer and the sixth leading cause of cancer death in the United States. The authors provide contemporary lymphoid neoplasm statistics by subtype based on the 2008 World Health Organization classifications, including the most current US incidence and survival data. Presented for the first time are estimates of the total numbers of US lymphoid neoplasm cases by subtype as well as a detailed evaluation of incidence and survival statistics. In 2016, 136,960 new lymphoid neoplasms are expected. Overall lymphoma incidence rates have declined in recent years, but trends vary by subtype. Precursor lymphoid neoplasm incidence rates increased from 2001 to 2012, particularly for B-cell neoplasms. Among the mature lymphoid neoplasms, the fastest increase was for plasma cell neoplasms. Rates also increased for mantle cell lymphoma (males), marginal zone lymphoma, hairy cell leukemia, and mycosis fungoides. Like incidence, survival for both mature T-cell lymphomas and mature B-cell lymphomas varied by subtype and by race. Patients with peripheral T-cell lymphomas had among the worst 5-year relative survival (36{\%}-56{\%}, depending on race/sex), while those with mycosis fungoides had among the best survival (79{\%}-92{\%}). For B-cell lymphomas, 5-year survival ranged from 83{\%} to 91{\%} for patients with marginal zone lymphoma and from 78{\%} to 92{\%} for those with hairy cell leukemia; but the rates were as low as 47{\%} to 63{\%} for patients with Burkitt lymphoma and 44{\%} to 48{\%} for those with plasma cell neoplasms. In general, black men had the lowest survival across lymphoid malignancy subtypes. These contemporary incidence and survival statistics are useful for developing management strategies for these cancers and can offer clues regarding their etiology.",
keywords = "Chronic lymphocytic leukemia, Epidemiology, Hodgkin disease, Multiple myeloma, Non-Hodgkin lymphoma",
author = "Teras, {Lauren R.} and Desantis, {Carol E.} and Cerhan, {James R} and Morton, {Lindsay M.} and Ahmedin Jemal and Flowers, {Christopher R.}",
year = "2016",
doi = "10.3322/caac.21357",
language = "English (US)",
journal = "CA Cancer Journal for Clinicians",
issn = "0007-9235",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - 2016 US lymphoid malignancy statistics by World Health Organization subtypes

AU - Teras, Lauren R.

AU - Desantis, Carol E.

AU - Cerhan, James R

AU - Morton, Lindsay M.

AU - Jemal, Ahmedin

AU - Flowers, Christopher R.

PY - 2016

Y1 - 2016

N2 - Collectively, lymphoid neoplasms are the fourth most common cancer and the sixth leading cause of cancer death in the United States. The authors provide contemporary lymphoid neoplasm statistics by subtype based on the 2008 World Health Organization classifications, including the most current US incidence and survival data. Presented for the first time are estimates of the total numbers of US lymphoid neoplasm cases by subtype as well as a detailed evaluation of incidence and survival statistics. In 2016, 136,960 new lymphoid neoplasms are expected. Overall lymphoma incidence rates have declined in recent years, but trends vary by subtype. Precursor lymphoid neoplasm incidence rates increased from 2001 to 2012, particularly for B-cell neoplasms. Among the mature lymphoid neoplasms, the fastest increase was for plasma cell neoplasms. Rates also increased for mantle cell lymphoma (males), marginal zone lymphoma, hairy cell leukemia, and mycosis fungoides. Like incidence, survival for both mature T-cell lymphomas and mature B-cell lymphomas varied by subtype and by race. Patients with peripheral T-cell lymphomas had among the worst 5-year relative survival (36%-56%, depending on race/sex), while those with mycosis fungoides had among the best survival (79%-92%). For B-cell lymphomas, 5-year survival ranged from 83% to 91% for patients with marginal zone lymphoma and from 78% to 92% for those with hairy cell leukemia; but the rates were as low as 47% to 63% for patients with Burkitt lymphoma and 44% to 48% for those with plasma cell neoplasms. In general, black men had the lowest survival across lymphoid malignancy subtypes. These contemporary incidence and survival statistics are useful for developing management strategies for these cancers and can offer clues regarding their etiology.

AB - Collectively, lymphoid neoplasms are the fourth most common cancer and the sixth leading cause of cancer death in the United States. The authors provide contemporary lymphoid neoplasm statistics by subtype based on the 2008 World Health Organization classifications, including the most current US incidence and survival data. Presented for the first time are estimates of the total numbers of US lymphoid neoplasm cases by subtype as well as a detailed evaluation of incidence and survival statistics. In 2016, 136,960 new lymphoid neoplasms are expected. Overall lymphoma incidence rates have declined in recent years, but trends vary by subtype. Precursor lymphoid neoplasm incidence rates increased from 2001 to 2012, particularly for B-cell neoplasms. Among the mature lymphoid neoplasms, the fastest increase was for plasma cell neoplasms. Rates also increased for mantle cell lymphoma (males), marginal zone lymphoma, hairy cell leukemia, and mycosis fungoides. Like incidence, survival for both mature T-cell lymphomas and mature B-cell lymphomas varied by subtype and by race. Patients with peripheral T-cell lymphomas had among the worst 5-year relative survival (36%-56%, depending on race/sex), while those with mycosis fungoides had among the best survival (79%-92%). For B-cell lymphomas, 5-year survival ranged from 83% to 91% for patients with marginal zone lymphoma and from 78% to 92% for those with hairy cell leukemia; but the rates were as low as 47% to 63% for patients with Burkitt lymphoma and 44% to 48% for those with plasma cell neoplasms. In general, black men had the lowest survival across lymphoid malignancy subtypes. These contemporary incidence and survival statistics are useful for developing management strategies for these cancers and can offer clues regarding their etiology.

KW - Chronic lymphocytic leukemia

KW - Epidemiology

KW - Hodgkin disease

KW - Multiple myeloma

KW - Non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84987643710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987643710&partnerID=8YFLogxK

U2 - 10.3322/caac.21357

DO - 10.3322/caac.21357

M3 - Article

AN - SCOPUS:84987643710

JO - CA Cancer Journal for Clinicians

JF - CA Cancer Journal for Clinicians

SN - 0007-9235

ER -